Tatva Chintan Shares Rise 17% After Strong Q1 Earnings And ₹200 Crore Expansion Plan

Tatva Chintan Pharma Chem reported a strong start to FY27 after its consolidated net profit more than doubled in the June quarter, supported by higher revenue and improved operating margins.

The speciality chemicals company posted a net profit of ₹16 crore for Q1 FY27, compared with ₹7 crore in the year-ago period, while revenue from operations rose 43% year-on-year to ₹167 crore from ₹116.8 crore.

Tatva Chintan Pharma Chem Ltd shares surged 20.00% to ₹1,713.70 at market closing on Monday as investors cheered the better-than-year-ago earnings.

The company announced its June quarter results after its board approved the unaudited standalone and consolidated financial statements at a meeting held on 17 July.

Why Did Tatva Chintan's Q1 FY27 Results Improve?

Tatva Chintan turned in a solid quarter, with operating performance clearly improving. Earning before interest, taxes, depreciation and amortisation (EBITDA) rose 86.6% to ₹32.1 crore, up from ₹17.2 crore, and margins climbed to 19.2% from 14.7%, pointing to stronger profitability.

This was the company's best quarter for EBITDA and profit after tax in five quarters, continuing a steady run of earnings gains.

The board also used the quarter to renew leadership: Mr Chintan Nitinkumar Shah, Mr Ajaykumar Mansukhlal Patel and Mr Shekhar Rasiklal Somani were each reappointed as Managing Director and Whole-time Directors for another three years.

What's Next For Tatva Chintan Pharma Chem?

The company has approved a ₹200 crore capacity expansion at its Dahej-III greenfield manufacturing facility in Gujarat. The project will add an aggregate reactor capacity of 344 kilolitres and will be funded through a mix of internal accruals and debt.

Tatva Chintan said the expansion is aimed at strengthening its manufacturing capabilities and supporting future growth. The company is also expanding its product portfolio across pharma intermediates, semiconductor chemicals and continuous flow chemistry, while continuing to invest in capacity to meet rising demand in the speciality chemicals segment.

Also Read - Five Of Top 10 Firms Add ₹1.54 Trillion In Market Value; TCS Leads Weekly Gains